WO2020253743A1 - 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 - Google Patents
8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 Download PDFInfo
- Publication number
- WO2020253743A1 WO2020253743A1 PCT/CN2020/096654 CN2020096654W WO2020253743A1 WO 2020253743 A1 WO2020253743 A1 WO 2020253743A1 CN 2020096654 W CN2020096654 W CN 2020096654W WO 2020253743 A1 WO2020253743 A1 WO 2020253743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parthenolide
- ethyleneimine
- hydrochloride
- preparation
- skin
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- n is 2-10000; because polyethyleneimine is a polymer, its molecular weight is not determined, but only a range, and the molecular weight range of polyethyleneimine is known to be 0-500000, and it is clear from experiments that at present From the polymerization of two ethylenediamines to polyethyleneimine with a molecular weight of 500,000, it is basically the polymerization of 20,000 to 10,000 ethylenediamines, so n in the structural formula is 2-10,000.
- the skin-improving skin care product includes a dosage form, and any dosage form that is clinically acceptable.
- the 8-ethyleneimine-parthenolide hydrochloride is the only active ingredient for anti-inflammatory repair, promoting the proliferation of epidermal fibroblasts, and improving the blood supply of the cortex; or 8-ethyleneimine-parthenolide hydrochloride
- the salt is combined with other substances to prepare the anti-inflammatory repair, promote the proliferation of epidermal fibroblasts, improve the blood supply of the skin and other skin care drugs.
- Example 1.8 A preparation method of ethyleneimine-parthenolide hydrochloride (Tanaclear)
- Polyethyleneimine (PEI) (5g) was added to 100mL of dichloromethane and stirred for 15min, and then directly added to parthenolide (300mg, 1.2mmol), stirred at room temperature for 3h; the solvent was removed under reduced pressure, and a small amount Dichloromethane was dissolved, quickly washed three times with water, dried with Na 2 SO 4 , filtered, and dichloromethane was removed under reduced pressure. The obtained crude product intermediate was dissolved in a small amount of dichloromethane again, and hydrogen chloride gas (with The equivalent of imine in polyethyleneimine). During stirring, observe the precipitation of white solid. When the white solid no longer separates, immediately stop the hydrogen chloride gas and continue stirring for 1 hour; collect the water phase and freeze-dry to obtain 8-Ethyleneimine-Parthenolide hydrochloride.
- PKI Polyethyleneimine
- Tanaclear significantly inhibits the enhancement of the transcriptional regulatory activity of the inflammatory factor NF- ⁇ B induced by LPS, and the effect is significantly better than the positive drugs dipotassium glycyrrhizinate and bisabolol, and its anti-inflammatory effect is equivalent to the effect of the glucocorticoid hydrocortisone.
- the anti-inflammatory treatment of skin care products also involves the repair of skin damage, and the proliferation of fibroblasts is the main manifestation.
- This part of the experiment detects the effects of Tanaclear and the three positive drugs dipotassium glycyrrhizinate (GK2), bisabolol (Drag) and hydrocortisone (Hydr) on the proliferation of fibroblast NIH-3T3.
- GK2 dipotassium glycyrrhizinate
- Drag bisabolol
- Hydr hydrocortisone
- Mouse fibroblasts NIH-3T3 were seeded in a 96-well plate at a density of 5000 cells/well, cultured in a 37°C, 5% CO 2 incubator for about 12 hours until the cells adhered, and appropriate concentrations of Tanaclear, GK2, Drag and Hydr were added to the corresponding In the well, a group of blank controls are set up at the same time, with 3 replicates in each group. After culturing for 48 hours, add 25 ⁇ L of MTT every time and incubate for 4 hours. Then DMSO dissolves the formazan and detects the OD490 absorbance value with a microplate reader, and performs statistical analysis on the data.
- Tanaclear significantly promotes the proliferation of fibroblasts, and the effect is better than the positive drugs dipotassium glycyrrhizinate and bisabolol, and its proliferation effect is equivalent to the effect of the glucocorticoid hydrocortisone.
- the six volunteers in the control group had no improvement in facial acne within 7 days; the acne removal rate in the Tanaclear group was 83.33%, and all acne marks were removed; the acne removal rate in the positive drug clindamycin phosphate gel group was 50%. The removal rate of acne marks was 16.67%.
- the improvement effect is shown as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (9)
- 一种根据权利要求1所述的8-乙烯亚胺-小白菊内酯盐酸盐的制备方法,其特征在于,包括以下步骤:1)以聚乙烯亚胺和小白菊内酯为起始原料,以二氯甲烷作为溶剂,经加成反应,得到小白菊内酯胺基加成产物;2)将步骤1)得到的小白菊内酯胺基加成产物与氯化氢气体或稀盐酸溶液反应成盐,得到目标产物8-乙烯亚胺-小白菊内酯盐酸盐。
- 根据权利要求2所述的制备方法,其特征在于:步骤1)中,加成反应结束后,用水将未反应完的聚乙烯亚胺清洗干净。
- 根据权利要求2所述的制备方法,其特征在于:步骤2)中,具体为:反应 液需边搅拌边通入氯化氢气体,通入氯化氢气体的过程中,逐渐有白色固体析出,通气至不再有白色固体析出,然后再继续搅拌1小时,保证全部小白菊内酯胺基加成产物与氯化氢气体反应得到目标产物8-乙烯亚胺-小白菊内酯盐酸盐。
- 根据权利要求2所述的制备方法,其特征在于:步骤2)中,具体为:边搅拌边加入稀盐酸溶液,搅拌期间要测量水溶液的pH值,当水溶液pH值为4-5时,停止滴加盐酸水溶液;保证全部小白菊内酯胺基加成产物与稀盐酸溶液反应得到目标产物8-乙烯亚胺-小白菊内酯盐酸盐。
- 权利要求1所述的8-乙烯亚胺-小白菊内酯盐酸盐在改善皮肤的护肤品中的应用。
- 根据权利要求6所述的应用,其特征在于:所述改善皮肤的护肤品为临床上可接受的任一剂型。
- 根据权利要求7所述的应用,其特征在于:8-乙烯亚胺-小白菊内酯盐酸盐为唯一活性成分。
- 根据权利要求1所述的8-乙烯亚胺-小白菊内酯盐酸盐与其他物质一起在制备所述抗炎修复、促进表皮层纤维细胞增殖、改善皮层供血护肤的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910542080.6 | 2019-06-21 | ||
CN201910542080.6A CN110642867B (zh) | 2019-06-21 | 2019-06-21 | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020253743A1 true WO2020253743A1 (zh) | 2020-12-24 |
Family
ID=69009356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/096654 WO2020253743A1 (zh) | 2019-06-21 | 2020-06-17 | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110642867B (zh) |
WO (1) | WO2020253743A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110642867B (zh) * | 2019-06-21 | 2020-07-21 | 上海澄穆生物科技有限公司 | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1498101A (zh) * | 2001-03-16 | 2004-05-19 | ���Ǿ� | 含有小白菊提取物的组合物及其用途 |
WO2005007103A2 (en) * | 2003-07-11 | 2005-01-27 | University Of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
CN101270102A (zh) * | 2007-06-22 | 2008-09-24 | 北京星昊医药股份有限公司 | 小白菊内酯衍生物的合成方法及其应用 |
WO2013152032A1 (en) * | 2012-04-02 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer |
CN108434133A (zh) * | 2018-06-11 | 2018-08-24 | 江苏食品药品职业技术学院 | 一种小白菊内酯用作骨形成蛋白9抑制剂的生物医药用途 |
CN110642867A (zh) * | 2019-06-21 | 2020-01-03 | 上海澄穆生物科技有限公司 | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107349128A (zh) * | 2017-08-21 | 2017-11-17 | 佛山市三水区嘉华化学研究院(普通合伙) | 一种促进吸收的面膜 |
-
2019
- 2019-06-21 CN CN201910542080.6A patent/CN110642867B/zh active Active
-
2020
- 2020-06-17 WO PCT/CN2020/096654 patent/WO2020253743A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1498101A (zh) * | 2001-03-16 | 2004-05-19 | ���Ǿ� | 含有小白菊提取物的组合物及其用途 |
WO2005007103A2 (en) * | 2003-07-11 | 2005-01-27 | University Of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
CN101270102A (zh) * | 2007-06-22 | 2008-09-24 | 北京星昊医药股份有限公司 | 小白菊内酯衍生物的合成方法及其应用 |
WO2013152032A1 (en) * | 2012-04-02 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer |
CN108434133A (zh) * | 2018-06-11 | 2018-08-24 | 江苏食品药品职业技术学院 | 一种小白菊内酯用作骨形成蛋白9抑制剂的生物医药用途 |
CN110642867A (zh) * | 2019-06-21 | 2020-01-03 | 上海澄穆生物科技有限公司 | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
ROBERT C. DELLER, DIAMANTI PARASKEVI, MORRISON GABRIELLA, REILLY JAMES, EDE BENJAMIN C., RICHARDSON ROBERT, LE VAY KRISTIAN, COLLI: "Functionalized Triblock Copolymer Vectors for the Treatment of Acute Lymphoblastic Leukemia", MOLECULAR PHARMACEUTICS, vol. 14, no. 3, 31 January 2017 (2017-01-31), pages 722 - 732, XP055766922, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.6b01008 * |
Also Published As
Publication number | Publication date |
---|---|
CN110642867A (zh) | 2020-01-03 |
CN110642867B (zh) | 2020-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bagher et al. | Conductive hydrogel based on chitosan-aniline pentamer/gelatin/agarose significantly promoted motor neuron-like cells differentiation of human olfactory ecto-mesenchymal stem cells | |
CN104136436B (zh) | 抗纤维化的化合物及其用途 | |
JP2013520462A (ja) | 抗炎症療法のためのケイ素含有生分解性物質 | |
Zhang et al. | Synthesis of methylprednisolone loaded ibuprofen modified inulin based nanoparticles and their application for drug delivery | |
WO2020253743A1 (zh) | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 | |
EP3838887A1 (en) | 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, preparation method therefor and uses thereof | |
CN108484795B (zh) | 硫酸软骨素锂及其制备方法和应用 | |
CN110054606B (zh) | 一种二氢杨梅素-盐酸黄连素药物共晶及制备方法 | |
CN104926976B (zh) | 糖胺聚糖类似物及其合成方法及其在体外胚胎干细胞增殖及定向神经分化中的应用方法 | |
CN108309944B (zh) | 注射用泮托拉唑钠及其制备方法 | |
CN109928931B (zh) | 含有苯并咪唑结构的磺酰胺类衍生物及其制备方法和用途 | |
Zhang et al. | The effects of Lactobacillus reuteri microcapsules on radiation-induced brain injury by regulating the gut microenvironment | |
AU2020230285A1 (en) | Use of bio-transformed bear bile powder in preparation of anti-inflammatory drugs | |
CN114957064B (zh) | 一种抑制mcu5ac分泌的化合物及其制药用途 | |
CN114452291B (zh) | 棒柄花苷a在制备抑制肝纤维化药物方面的应用 | |
Moreno et al. | UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases | |
CN115894437B (zh) | 一种丁香酚硫化氢衍生物及其制备方法与应用 | |
WO2023082218A1 (zh) | 纳米硒海藻酸钠复合凝胶及制备方法和应用 | |
CN109232662B (zh) | 抗肿瘤作用的化合物及其制备方法和应用 | |
CN107375480A (zh) | 大承气汤在制备防治帕金森氏病药物中的应用 | |
CN107375479A (zh) | 大承气汤在制备改善由中枢炎症造成的老年痴呆药物中的应用 | |
CN108743633B (zh) | 藤梨根总三萜类化合物与藤梨根多糖联用在制备消化系统肿瘤和肺癌防治药物中的应用 | |
CN115957345A (zh) | 一种用于变应性鼻炎治疗的pH响应性靶向纳米递送系统及其制备方法和应用 | |
CN112168773A (zh) | 含嘧啶-2,4-二胺衍生物的抗癌用药物的制备方法 | |
Wang et al. | A carrier-free organometallic hydrogel originated from natural baicalin and Zn2+ with antibacterial and antioxidant efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20827613 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20827613 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/05/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20827613 Country of ref document: EP Kind code of ref document: A1 |